BB Biotech achieves record results in 2014
(Thomson Reuters ONE) -
BB BIOTECH AG /
BB Biotech achieves record results in 2014
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Publication of BB Biotech AG's Annual Report for 2014
Significant increase of 65% in tax-efficient cash distribution to CHF 11.60 per
share
BB Biotech AG's net profit for 2014 amounts to CHF 1.47 bn - the highest profit
for the year reported by the Swiss investment company since its establishment in
1993. While 2014 was generally a good year for the sector, BB Biotech's record
results are largely attributable to its investment strategy and stock selection.
Its distribution policy remains unchanged with a tax-efficient cash distribution
(free of Swiss withholding tax) of CHF 11.60 per share, to be proposed at the
Annual General Meeting. This represents a 65% increase compared to last year. BB
Biotech remains positive on the sector - the R&D pipelines of biotech companies
are well filled and sector profits should continue growing at a strong pace in
2015.
BB Biotech looks back on its most successful year since its founding in 1993:
Its investment strategy paid off once again and the Net Asset Value (NAV)
increased 72.3% in CHF or 75.8% in EUR and 54.6% in USD, which beat the
benchmark performance (Nasdaq Biotech Index in USD) by 20 percentage points. BB
Biotech's annual share performance was 75.1% in CHF and 79.3% in EUR (all values
include the cash distribution of CHF 7.00 per share). For the fiscal year 2014,
net profit reached a record high of CHF 1.47 bn, well above the previous year's
result of CHF 931.8 mn. The core holdings of Celgene, Isis, Incyte, Actelion and
Agios were major performance drivers for BB Biotech's portfolio, each making a
positive contribution of more than CHF 100 mn to the overall full-year
performance. Smaller positions such as Puma and Receptos also made a notable
contribution thanks to convincing clinical data.
BB Biotech is sticking to its selectively focused portfolio strategy, consisting
of core shareholdings plus various mid-cap names that have innovative technology
and/or are pursuing novel avenues of treatment. This investment strategy is not
bound by any benchmark indices, a fact that has helped BB Biotech to outperform
sector indices by a wide margin in the past.
In line with the distribution policy established in 2013, the Board of Directors
will propose a tax-efficient cash distribution of CHF 11.60 per share at the
Annual General Meeting. This represents a significant increase of 65% compared
to the previous year and corresponds to a yield of 5% based on the volume
weighted average share price in December 2014.
In view of the product candidates moving through the pipelines of biotech
companies, it is likely that the sector will bring new, highly effective drugs
to market in 2015. That should help to support sector momentum along with
continued earnings growth.
BB Biotech's annual report as of December 31, 2014, is available at
www.bbbiotech.com.
For further information:
Investor Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel.
+41 44 267 67 00
Dr. Silvia Schanz, ssc(at)bellevue.ch
Maria-Grazia Iten-Alderuccio, mga(at)bellevue.ch
Claude Mikkelsen, cmi(at)bellevue.ch
Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel.
+41 44 267 67 00
Tanja Chicherio, tch(at)bellevue.ch
b-public AG, Pfingstweidstrasse 6, 8005 Zürich, Switzerland, Tel.
+41 79 423 22 28
Thomas Egger, teg(at)b-public.ch
www.bbbiotech.com
Company profile
BB Biotech invests in companies in the fast growing market of biotechnology and
is one of the world's largest investors in this sector with CHF 3.5 bn in assets
under management. BB Biotech is listed in Switzerland, Germany and Italy. Its
investments are focused on listed companies that are developing and
commercializing novel medical treatments and cures. BB Biotech's investment
selection process is guided by the fundamental research and analysis of
physicians and molecular biologists. Its Board of Directors has many years of
experience in industry and science.
Disclaimer
This release contains forward-looking statements and expectations as well as
assessments, beliefs and assumptions. Such statements are based on the current
expectations of BB Biotech, its directors and officers, and are, therefore,
subject to risks and uncertainties that may change over time. As actual
developments may significantly differ, BB Biotech and its directors and officers
accept no responsibility in that regard. All forward-looking statements included
in this release are made only as of the date of this release and BB Biotech and
its directors and officers assume no obligation to update any forward-looking
statements as a result of new information, future events or other factors.
Press Release (PDF):
http://hugin.info/130285/R/1895920/672501.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: BB BIOTECH AG via GlobeNewswire
[HUG#1895920]
Datum: 20.02.2015 - 07:00 Uhr
Sprache: Deutsch
News-ID 373030
Anzahl Zeichen: 6299
contact information:
Town:
Schaffhausen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 270 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BB Biotech achieves record results in 2014"
steht unter der journalistisch-redaktionellen Verantwortung von
BB BIOTECH AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
